Primecap Management
NBIX icon

Primecap Management’s Neurocrine Biosciences NBIX Stock Holding History

Primecap Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.8M Sell
491,340
-5,000
-1% -$742K 0.05% 169
2026
Q1 		$65.4M Sell
496,340
-11,400
-2% -$1.51M 0.05% 177
2025
Q4 		$72M Sell
507,740
-4,520
-0.9% -$655K 0.05% 173
2025
Q3 		$71.9M Sell
512,260
-11,780
-2% -$1.6M 0.06% 177
2025
Q2 		$65.9M Buy
524,040
+141,600
+37% +$16.2M 0.05% 176
2025
Q1 		$42.3M Sell
382,440
-11,270
-3% -$1.43M 0.04% 194
2024
Q4 		$53.7M Sell
393,710
-10,290
-3% -$1.27M 0.04% 180
2024
Q3 		$46.5M Sell
404,000
-5,290
-1% -$725K 0.03% 193
2024
Q2 		$56.3M Buy
409,290
+9,910
+2% +$1.36M 0.04% 181
2024
Q1 		$55.1M Buy
399,380
+1,057
+0.3% +$144K 0.04% 183
2023
Q4 		$52.5M Buy
398,323
+6,738
+2% +$776K 0.04% 183
2023
Q3 		$44.1M Sell
391,585
-1,775
-0.5% -$187K 0.04% 187
2023
Q2 		$37.1M Buy
393,360
+21,620
+6% +$2.11M 0.03% 197
2023
Q1 		$37.6M Buy
371,740
+366,640
+7,189% +$38.2M 0.03% 190
2022
Q4 		$609K Buy
+5,100
New +$597K ﹤0.01% 324

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Primecap Management's NBIX Position: Q2 2026 in Review

Primecap Management reduced its Neurocrine Biosciences (NBIX) stake by 1% in Q2 2026, selling an estimated $742K and leaving 491,340 shares worth $82.8M. The position accounts for 0.05% of the portfolio, ranked #169.

Primecap Management first reported a position in NBIX in Q4 2022 and has held it in 15 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Primecap Management held 491,340 shares of Neurocrine Biosciences worth $82.8M as of Q2 2026.
  • Primecap Management sold 5,000 Neurocrine Biosciences shares in Q2 2026, an estimated $742K.
  • Neurocrine Biosciences made up 0.05% of Primecap Management's portfolio in Q2 2026, its #169 holding.
  • Primecap Management first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 15 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Primecap Management's 13F filing for Q2 2026, filed 14 Aug 2026.